CN112105620A - 用于治疗肺癌的tlr7激动剂及其药物组合 - Google Patents
用于治疗肺癌的tlr7激动剂及其药物组合 Download PDFInfo
- Publication number
- CN112105620A CN112105620A CN201980033499.7A CN201980033499A CN112105620A CN 112105620 A CN112105620 A CN 112105620A CN 201980033499 A CN201980033499 A CN 201980033499A CN 112105620 A CN112105620 A CN 112105620A
- Authority
- CN
- China
- Prior art keywords
- pyrrolo
- pyrimidin
- butoxy
- amine
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本申请涉及用于治疗肺癌的作为Toll样受体7(TLR7)激动剂的式I化合物或其药学上可接受的盐,用于治疗肺癌的TLR7激动剂和酪氨酸激酶抑制剂的药物组合,以及式I化合物或其药学上可接受的盐所述药物组合在治疗肺癌中的用途。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810560770 | 2018-05-25 | ||
CN201810560770X | 2018-05-25 | ||
PCT/CN2019/088360 WO2019223788A1 (zh) | 2018-05-25 | 2019-05-24 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112105620A true CN112105620A (zh) | 2020-12-18 |
Family
ID=68616579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980033499.7A Pending CN112105620A (zh) | 2018-05-25 | 2019-05-24 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210220362A1 (zh) |
EP (1) | EP3816166A4 (zh) |
JP (1) | JP7385602B2 (zh) |
KR (1) | KR20210013183A (zh) |
CN (1) | CN112105620A (zh) |
CA (1) | CA3101370A1 (zh) |
WO (1) | WO2019223788A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022156678A1 (zh) * | 2021-01-20 | 2022-07-28 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2477987T3 (pl) * | 2009-09-14 | 2018-06-29 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych |
CN105311029A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
US9962388B2 (en) * | 2014-08-15 | 2018-05-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
MY189991A (en) | 2015-11-05 | 2022-03-22 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | 7-(thiazol-5-yl)pyrrolopyrimidine compound as tlr7 agonist |
CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
CN107043377A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
-
2019
- 2019-05-24 CN CN201980033499.7A patent/CN112105620A/zh active Pending
- 2019-05-24 WO PCT/CN2019/088360 patent/WO2019223788A1/zh unknown
- 2019-05-24 JP JP2020565840A patent/JP7385602B2/ja active Active
- 2019-05-24 KR KR1020207037107A patent/KR20210013183A/ko unknown
- 2019-05-24 EP EP19807809.9A patent/EP3816166A4/en active Pending
- 2019-05-24 CA CA3101370A patent/CA3101370A1/en active Pending
- 2019-05-24 US US17/058,979 patent/US20210220362A1/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022156678A1 (zh) * | 2021-01-20 | 2022-07-28 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
CN115119508A (zh) * | 2021-01-20 | 2022-09-27 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
CN115119508B (zh) * | 2021-01-20 | 2024-05-24 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
AU2019272478A1 (en) | 2020-12-17 |
JP7385602B2 (ja) | 2023-11-22 |
CA3101370A1 (en) | 2019-11-28 |
EP3816166A4 (en) | 2022-04-06 |
US20210220362A1 (en) | 2021-07-22 |
JP2021525260A (ja) | 2021-09-24 |
WO2019223788A1 (zh) | 2019-11-28 |
KR20210013183A (ko) | 2021-02-03 |
EP3816166A1 (en) | 2021-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110382499B (zh) | Fgfr抑制剂及其应用 | |
TWI726363B (zh) | Fak/alk/ros1抑制劑與egfr抑制劑的組合治療癌症的方法 | |
US20220363648A1 (en) | Glucose Uptake Inhibitors | |
TW201915004A (zh) | 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用 | |
TW202304914A (zh) | 經取代之四環羧酸、其類似物及使用其之方法 | |
CN112839947B (zh) | 用于治疗结直肠癌的tlr7激动剂及其药物组合 | |
US20210251991A1 (en) | Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
CN112105620A (zh) | 用于治疗肺癌的tlr7激动剂及其药物组合 | |
KR20210063332A (ko) | 퀴놀린카르복사미드 유도체를 사용하는 암 병용 요법 | |
AU2019272478B2 (en) | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer | |
TW202132285A (zh) | 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法 | |
JP2023507028A (ja) | 複素環式化合物とその医薬組成物、調製方法、中間体及び使用 | |
EP4029503A1 (en) | Drug combination containing tlr7 agonist | |
CN112759583B (zh) | 包含呋喃基的喹啉类衍生物及其制备方法和用途 | |
CN112625025B (zh) | 吡啶基取代的喹啉类衍生物及其制备方法和用途 | |
CN114105977B (zh) | 雌激素受体调节剂化合物及其用途 | |
US11795179B2 (en) | Discovery of imidazothiazole- and imidazooxazole-based selective HER4 kinase inhibitors as potential anticancer agents | |
CN113164487A (zh) | 磷酸二酯酶抑制剂 | |
US20240051940A1 (en) | Sulfonamides with egfr inhibition activities and their use thereof | |
TW202400578A (zh) | 新穎的化合物及其用於抑制檢查點激酶2的用途 | |
CN116261455A (zh) | 一种药物组合物及其在治疗癌症中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40039547 Country of ref document: HK |